ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 2529

Comparative Effectiveness of Denosumab versus Zoledronic Acid Among Postmenopausal Women with Osteoporosis in the U.S. Medicare Program
Abstract Number: 2530

Risk Evaluation of Osteoporotic Fractures Following Lung Transplantation (LT): A Retrospective Cohort Study Conducted at an International Transplant Center
Abstract Number: 2531

Proton Pump Inhibitor Use Is Associated with Impaired Bone Mineral Density but Not Bone Microarchitecture in Patients with Inflammatory Rheumatic and Musculoskeletal Diseases Taking Glucocorticoids
Abstract Number: 2532

Prevalence and Disease-Specific Factors Associated with Osteoporosis in Systemic Sclerosis: A Cross-Sectional Analysis of Two Large European Cohorts
Abstract Number: 2533

Real-world Evidence for Assessing Mortality Disparity Between the Patients with Rheumatoid Arthritis and the General Population in Japan: Results from the IORRA Study
Abstract Number: 2534

A Novel Approach for Mixed-methods Research Using Language Learning Models: A Report Using Patients’ Perspectives on Barriers to Hip and Knee Replacement
Abstract Number: 2535

Strategies to Embrace Living with Lupus Fearlessly (SELF): A Promising Digital Intervention for Lupus Self-Management
Abstract Number: 2536

DMARD Adherence During the COVID-19 Pandemic and Association with Risk of COVID-19 Infection
Abstract Number: 2537

Implementation of a Best Practice Advisory to Improve Infection Screening Prior to New Prescriptions of Biologics and Targeted Synthetic Drugs
Abstract Number: 2538

Safety and Efficacy of Sodium-glucose Co-transporter 2 Inhibitors in Patients with Psoriasis and Concomitant Type 2 Diabetes Mellitus: A Population-based Cohort Study
Abstract Number: 2539

Baseline IL-10 Levels as a Predictive Biomarker for Achieving Clinical Response with Abatacept in ACPA+ Patients with Early RA
Abstract Number: 2540

The Molecular Stratification of Rheumatoid Arthritis Using High-throughput Technologies Is Directly Associated with Disease Activity and Clinical Response
Abstract Number: 2541

Differential Responses to Initial Treatment Strategies for Rheumatoid Arthritis Among Those with Lower Body Mass and Adiposity
Abstract Number: 2542

Impact of Concomitant Methotrexate on Disease Activity After Tapering Abatacept in Patients with Rheumatoid Arthritis: A Nationwide Cohort Study
Abstract Number: 2543

Clinical and Radiographic Results of Tapering and Withdrawing CsDMARDs versus Stable Treatment in Patients with Rheumatoid Arthritis in Remission: 3-year Results from a Randomized Controlled Trial

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].